Table 2.
Haploidentical donor transplant for FA
| Ref | Alloreactive donor T cell Reduction method | n= | Neutrophil Engraftment | Graft Failure | GVHD (Grade III/IV acute, chronic) | Overall survival | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| CD34+ selection | Elhasid 2000 [62] | 1st Haplo: CD34+ selection (5 × 104 CD3+ cells/kg) ATG (d-6/4/2, +2/4/6/8/10/12) |
1 | Day +8 | Yes | None, NA | Alive (+2 yrs) |
| 2nd Haplo: CD34+ selection (3 × 104 CD3+ cells/kg) ATG (d-5 to -1) |
Day +10 | No | None, None | ||||
|
| |||||||
| Rossi 2003 [63] | CD34+ selection (1 × 104 CD3+ cells/kg) ATG (d-6 to -3) |
1 | Day +12 | No | None, None | Alive (+18 mon) | |
|
| |||||||
| Dufort 2012 [64] | CD34+ selection and OKT3 depletion (median 1.15 × 105 CD3+/kg) ATG (d-6 to -3) |
3 | 100% (median d+11) | 0% | 0%, 0% | 100% (+5,6,16 mon) | |
|
| |||||||
| Zecca 2014 [65] | CD34+ selection (median of 1.4 × 104 CD3+/kg) ATG (d -6 to -3) |
12 | 75% (median d+12) | 17% | 0%, 35% | 83% (+5 yr) | |
|
| |||||||
| TCR αβ+ depletion | Bertaina 2014 [66] | TCR αβ+ depletion (median 4 × 104 TCR αβ+ CD3+/kg ATG (d-5 to -3) |
4 | 100% (median d+13) | 0% | 0%, 0% | 100% (+18 mon) |
|
| |||||||
| PTCy | Thakar 2012 [67] | PTCy 25 mg/kg × 2 d | 3 | 100% (median d+15) | 0% | 33%, 33% | 67% (+2, 3 yrs) |
|
| |||||||
| CAMPATH | Rihani 2010 [68] | Alemtuzumab 0.2 mg/kg in donor cell bag (9.4 × 106 CD3+ cells/kg) ATG (d-6 to -2) |
1 | Day +9 | No | None, None | Alive (+15 mon) |
|
| |||||||
| Fetomaternal microchimerism | Yabe 2004 [69] | NIMA 1/10,000 chimeric level identified in 1 pt, not determined in 1 pt ATG x 4 days |
2 | 100% (median d+18) | No | 0%, 100% | Alive (+18, 30 mon) |
GVHD, graft versus host disease; Haplo, haploidentical stem cell transplant; NA, not applicable; ATG, anti-thymocyte globulin; TCR, T cell receptor; PTCy, post-transplant cyclophosphamide